Docket Room.
HR 9661·Federal·house

Expedited Access to Biosimilars Act

In Committee
Sponsor: Rep. Langworthy, Nicholas A. [R-NY-23] (R)
Latest Action

Referred to the House Committee on Energy and Commerce.

Jul 14, 2026

Email me when HR 9661 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track HR 9661. By continuing you agree to the Terms and Privacy Policy.

Legislative status

  1. Introduced
  2. In Committee
  3. Reported by Committee
  4. Floor Vote Scheduled
  5. Passed One Chamber
  6. Passed Both Chambers
  7. Sent to Executive
  8. Signed into Law

Summary

The bill changes the Public Health Service Act so that, by default, companies seeking approval for biosimilar biological products will not have to conduct clinical studies on pharmacodynamics or comparative clinical efficacy. This affects drug manufacturers, the FDA, and patients who may see faster, lower‑cost access to biosimilars. The goal is to reduce development burdens while maintaining safety standards.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about HR 9661

3 free questions a day, no account

Hearings

Sponsors

  • Rep. Langworthy, Nicholas A. [R-NY-23] (R) · sponsor

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when HR 9661 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track HR 9661 free

Or ask your AI assistant about HR 9661 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice